Figures computed from official regulatory filings — .
Ownershipinsiders 6.57% · institutions 77.24% · short 8.6% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BIORA THERAPEUTICS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On May 27, 2025, the voluntary petition of Biora Therapeutics, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 27, 2024.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
19 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| dEsparbes Eric | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Neumann Clarke | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| dEsparbes Eric | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Neumann Clarke | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hashemi Hutan | Other | $355.3 | SEC |
| dEsparbes Eric | Other | $9.3K | SEC |
| Neumann Clarke | Other | $3.3K | SEC |
| Hashemi Hutan | Other | $2.2K | SEC |
| Cooper Matthew T | Other | $2.4K | SEC |
| Neumann Clarke | Other | $2.6K | SEC |
| Silvestry Damon | Other | $15.8K | SEC |
| MOHANTY ADITYA P. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MOHANTY ADITYA P. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Howe Jill Ann | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Howe Jill Ann | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| dEsparbes Eric | Other | $9.5K | SEC |
| Cooper Matthew T | Other | $929.6 | SEC |
| Neumann Clarke | Other | $3.9K | SEC |
| Silvestry Damon | Other | $2.5K | SEC |
| Stylli Harrytrack record | Other | $17.2K | SEC |
| Hashemi Hutan | Other | $262.3 | SEC |
| Seelye Troy | Other | $45.9K | SEC |
| Sarna Surbhi | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sarna Surbhi | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kotzin Brian L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |